Immunome, Inc. short interest in 2021
In 2021, Immunome, Inc.'s disclosed short interest ran from 2.22% of shares outstanding on 31 Mar 2021 to 2.00% on 31 Dec 2021, a change of -0.22 percentage points. The year's high was 2.78% on 31 Aug 2021 and its low 1.63% on 13 Aug 2021, averaging 2.07% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.70 days on 15 Jul 2021. Full history: Immunome, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 2.22% (31 Mar 2021)
- End of year
- 2.00% (31 Dec 2021)
- Change
- -0.22 pp
- High
- 2.78% (31 Aug 2021)
- Low
- 1.63% (13 Aug 2021)
- Average
- 2.07%
- Highest days to cover
- 5.70 (15 Jul 2021)
- SEC filings marked
- 6
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 31 Mar 2021 | 2.22% | 2.80 | 10-K filed, results (8-K) |
| 15 Apr 2021 | 1.80% | 3.74 | |
| 30 Apr 2021 | 2.13% | 1.65 | |
| 14 May 2021 | 2.18% | 3.14 | 10-Q filed, results (8-K) |
| 28 May 2021 | 2.28% | 2.43 | |
| 15 Jun 2021 | 2.13% | 2.70 | |
| 30 Jun 2021 | 1.96% | 2.22 | |
| 15 Jul 2021 | 1.98% | 5.70 | |
| 30 Jul 2021 | 1.91% | 1.00 | |
| 13 Aug 2021 | 1.63% | 1.81 | |
| 31 Aug 2021 | 2.78% | 3.90 | 10-Q filed |
| 15 Sep 2021 | 2.38% | 1.23 | |
| 30 Sep 2021 | 2.20% | 1.16 | |
| 15 Oct 2021 | 1.80% | 1.38 | |
| 29 Oct 2021 | 1.98% | 2.16 | |
| 15 Nov 2021 | 1.81% | 2.45 | 10-Q filed |
| 30 Nov 2021 | 1.81% | 1.50 | |
| 15 Dec 2021 | 2.41% | 3.02 | |
| 31 Dec 2021 | 2.00% | 3.14 |
See also: Immunome, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.